Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
Browsing: Clinical trials
Biogen and Eisai have announced the decision to discontinue the global Phase III trials of aducanumab for Alzheimer’s disease.
Two clinical trials of a combined therapy targeting the opioid system have suggested significant symptom reduction in people with major depression.
Scientists have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s, which may explain why many drug trials have failed.
Research presented at AAIC reveals the development of the National Strategy and how community based outreach increases participation in Alzheimer’s research.
A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.
An independent data monitoring committee has advised that lanabecestat is unlikely to meet primary endpoints, leading to the decision to discontinue trials.
Aleksandar Videnovic speaks with Lauren Pulling on what a career in clinical trials involves, including the challenges and rewarding aspects.
In this week’s industry news round-up we set the focus on Alzheimer’s disease (AD), with another clinical trial termination announced and a new framework for defining AD.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.